Skip to Main Content

Hello, everyone, and how are you today? We are just fine, thank you, now that the short person has made the trip to the local schoolhouse and the officials mascots are quietly ensconced in their official snoozing positions. As for us, we are quaffing the usual cups of stimulation — we are trying vanilla creme brulee, for those who track this sort of thing — and scrounging about for interesting items. On that note, here are some tidbits. Have a lovely day and, as always, do keep in touch …

John Kapoor, the founder of Insys Therapeutics (INSY) who was indicted last week for allegedly participating in a scheme to bribe doctors and illegally market the Subsys opioid painkiller, resigned on Monday as chairman of Akorn (AKRX), another drug maker that he has largely controlled. In a brief statement, the company, which recently agreed to be acquired by Fresnius Kabi, says his departure is not related to “operations, policies or practices.”


Novartis (NVS) filed for U.S. approval for its Kymriah CAR-T therapy to treat the most common type of non-Hodgkin lymphoma among adults, PharmaPhorum notes. This would be the second use of the drug in the U.S. market and would place Novartis in competition with Gilead Sciences (GILD), which more recently won regulatory approval of its Yescarta therapy to treat the same aggressive form of cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!